For patients with mainly mild posterior circulation ischemic stroke who do not receive thrombectomy, alteplase administered at 4.5 to 24 hours after onset results in higher frequency of functional ...
PRAGUE, Czech Republic — A 0.4-mg/kg bolus dose of tenecteplase (TNKase, Genentech) was associated with functional outcomes and safety similar to those seen with the standard of care, alteplase ...
Please provide your email address to receive an email when new articles are posted on . In a phase 2 study, reteplase demonstrated similar efficacy and safety vs. alteplase for the treatment of acute ...
Safe and Cost Effective Use of Alteplase for the Clearance of Occluded Central Venous Access Devices
Phase I and Pharmacologic Study of Oral ZD9331, A Novel Nonpolyglutamated Thymidylate Synthase Inhibitor, in Adult Patients With Solid Tumors PURPOSE: To determine whether cryopreserved solutions of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results